Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
CorMedix Inc (CRMD) operates at the intersection of infectious disease treatment and acute care medicine, making its news coverage particularly relevant for investors tracking the specialty pharmaceutical sector. As a company commercializing antimicrobial solutions and developing new therapies, CorMedix generates news spanning clinical trial milestones, regulatory decisions, and commercial expansion.
Biopharmaceutical companies like CorMedix produce news that directly impacts valuation and investment decisions. Clinical trial data releases, FDA communications, and real-world evidence studies can significantly affect stock performance. This news page consolidates coverage of DefenCath commercial developments, pipeline progress for products like REZZAYO, and corporate transactions including acquisitions and strategic investments.
Beyond pipeline updates, CorMedix news includes quarterly financial results, revenue guidance revisions, and capital market activities. The company's acquisition strategy and partnerships create additional newsworthy events. Healthcare technology designations, institutional recognition, and payer coverage decisions also factor into the company's news flow.
Bookmark this page to track CorMedix developments including earnings announcements, clinical data presentations, and material corporate events that drive stock price movements in the specialty pharmaceutical space.
CorMedix (NASDAQ: CRMD) has announced the completion of enrollment in its Phase III ReSPECT clinical trial for REZZAYO® (rezafungin). The study evaluates REZZAYO as a prophylactic treatment against Candida, Aspergillus, and Pneumocystis infections in patients undergoing allogeneic blood and marrow transplantation.
The trial, sponsored by Mundipharma, compares once-weekly REZZAYO to standard antimicrobial treatment. The dosing regimen includes a 400 mg loading dose followed by 200 mg weekly for 13 weeks. Topline results are expected in Q2 2026. The study's primary endpoint is fungal-free survival at day 90, with secondary endpoints including IFD incidence, toxicity-related discontinuation, and mortality.
CorMedix (NASDAQ:CRMD) has announced a strategic $5 million minority investment in Talphera (NASDAQ:TLPH), acquiring 9,090,909 shares at $0.55 per share. The investment is part of Talphera's private placement financing to fund its Phase 3 study of Niyad™, a breakthrough-designated anticoagulant for extracorporeal circuits.
As part of the deal, CorMedix receives exclusive first negotiation rights for a potential Talphera acquisition, with a 60-day exclusive period following Phase 3 results. Additionally, CorMedix gains the right to nominate one director to Talphera's board. Niyad targets an estimated 165,000 acute kidney injury patients annually who receive CRRT treatment and cannot tolerate heparin.
Talphera (NASDAQ:TLPH) has secured a private placement financing of up to $29 million led by CorMedix Inc. as the strategic investor, along with institutional investors including Nantahala Capital, Rosalind Advisors, and Rock Springs Capital. The financing includes $17 million in the first closing (expected September 10, 2025) and potential $12 million in a second tranche upon achieving the primary endpoint in the NEPHRO CRRT study.
The first closing involves issuing 25,036,363 shares at $0.55 per share and 5,845,455 pre-funded warrants at $0.549. CorMedix receives a 60-day exclusivity period to negotiate Talphera's acquisition following NEPHRO study results and gains board nomination rights. The funding is expected to support Talphera through the planned Niyad PMA approval in H2 2026.
CorMedix (NASDAQ:CRMD) has completed its acquisition of Melinta Therapeutics in a transformational deal valued at $300 million, comprising $260 million in cash and $40 million in equity. The acquisition brings seven marketed products to CorMedix's portfolio and is expected to generate significant financial benefits.
The company has raised its financial guidance, projecting pro forma 2025 combined revenues of $325-350 million and pro forma synergized adjusted EBITDA of $165-185 million. The transaction is expected to achieve annual run-rate synergies of $35-45 million and be accretive to EPS with double-digit accretion in 2026.
The deal includes potential additional payments of up to $25 million tied to regulatory milestones for REZZAYO™'s expanded indication, which could generate peak annual sales exceeding $200 million if approved.
CorMedix (NASDAQ:CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening conditions, announced its participation in two major healthcare investor conferences in September 2025.
The company's senior management will present at the Cantor Global Healthcare Conference on September 5 at 8:35am ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 at 10:45am ET. Both presentations will be in a fireside chat format with webcasts available.
CorMedix (NASDAQ: CRMD) has announced a strategic acquisition of Melinta Therapeutics in a transformational deal valued at $300 million upfront, consisting of $260 million in cash and $40 million in CorMedix equity. The agreement includes an additional $25 million regulatory milestone payment and royalties.
Since its 2020 private acquisition by Deerfield Management, Melinta has achieved 85% revenue growth and profitability. The merger will expand CorMedix's portfolio with seven marketed products, including REZZAYO®, MINOCIN®, VABOMERE®, KIMYRSA®, ORBACTIV®, BAXDELA®, and TOPROL-XL®. A Phase III study for REZZAYO® is expected to complete in 1H2026.
The transaction is expected to close in September 2025, subject to regulatory approvals.
CorMedix (NASDAQ:CRMD) reported strong Q2 2025 financial results, highlighted by $39.7 million in net revenue from DefenCath sales, compared to $0.8 million in the same period last year. The company achieved net income of $19.8 million ($0.29 per share), a significant turnaround from a net loss of $14.2 million in Q2 2024.
For the first half of 2025, CorMedix recorded $78.8 million in net revenue and net income of $40.5 million ($0.60 per share). The company maintains a strong financial position with $190.7 million in cash and short-term investments. Operating expenses increased 18% year-over-year to $18.3 million in Q2 2025.
In a significant strategic move, CorMedix announced the acquisition of Melinta Therapeutics LLC, with an expected closing date of September 1, 2025.
CorMedix (NASDAQ:CRMD) has announced a transformational acquisition of Melinta Therapeutics for $300 million in upfront consideration, including $260M in cash and $40M in CRMD equity. The deal adds seven marketed products to CorMedix's portfolio and is expected to generate pro forma 2025 combined revenues of $305-335 million.
The acquisition brings significant strategic value with expected annual run-rate synergies of $35-45 million and is projected to be accretive to EPS with double-digit accretion in 2026. The deal includes potential additional payments of up to $25 million in regulatory milestones and royalties on REZZAYO™ and MINOCIN® sales.
The transaction is expected to close by September 1, 2025, subject to HSR Act requirements. Melinta's portfolio, which generated $120 million in 2024 revenue, includes key products like REZZAYO™, which has potential peak sales exceeding $200 million in its expanded indication.
CorMedix (NASDAQ:CRMD), a biopharmaceutical company, has announced the pricing of its public offering of 6,604,507 shares of common stock. The offering is expected to generate gross proceeds of approximately $85 million. The company has also granted underwriters a 30-day option to purchase up to an additional 15% of shares.
The offering is expected to close around June 30, 2025, with RBC Capital Markets acting as sole bookrunner. CorMedix plans to use the proceeds for general corporate purposes, including working capital, research and development expenses, and potential strategic transactions.
CorMedix (NASDAQ:CRMD), a biopharmaceutical company, has announced plans for a $85.0 million public offering of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price, less underwriting discounts and commissions.
RBC Capital Markets is serving as the sole bookrunner for the offering. The proceeds will be used for general corporate purposes, including working capital, research and development expenses, and potential strategic transactions such as acquisitions, joint ventures, or collaborations.
FAQ
What is the current stock price of Cormedix (CRMD)?
What is the market cap of Cormedix (CRMD)?
